Seegnal to release MetricsGuard in Q4 2025

Executive Summary

• Seegnal Inc. has completed development of its new "MetricsGuard" clinical decision support module, which extends its existing software to detect single-drug-to-patient metric risks (e.g., hypoglycemia with sulphonylureas) rather than just drug-to-drug interactions.
• The company anticipates releasing the module in the fourth quarter of 2025 and has already secured the first two customer orders.
• MetricsGuard aims to reduce adverse drug effects by providing real-time, personalized alerts for contraindicated conditions, potentially lowering healthcare costs and clinician burnout.

Key Details

• Product Name: MetricsGuard clinical decision support module.
• Functionality: An intelligent layer that analyzes patient-specific data (lab results, vital signs, serum drug levels) to detect risks associated with single medications, such as:
  • Hypoglycemia and sulphonylureas.
  • Hyponatremia and diuretics.
  • Bradycardia and beta blockers.
  • Hypocalcemia and denosumab.
  • Toxicity predisposing factors (hypokalemia/hypomagnesemia) and digoxin.
• Release Timeline: Anticipated release in the fourth quarter of 2025.
• Commercial Status: First two customer orders have been signed.
• Strategic Value: Designed to replace the current drug-to-drug interaction standard, which Seegnal cites as ineffective based on a U.S. National Library of Medicine study regarding prescription drug-related morbidity and mortality.
• CEO Commentary: Eyal Schneid states the module will differentiate Seegnal from legacy competitors, save money by decreasing emergency care/hospitalizations, reduce clinician burnout, and improve patient quality of life.

Notable Quotes

• "This module will further differentiate and distinguish Seegnal from its legacy competitors, providing unmatched, yet much needed clinical value. This module will directly save money to healthcare organizations by decreasing the number of emergency care, hospitalization and revisits, decrease clinicians burnout, and improve patient quality of living." — Eyal Schneid